Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014755 · ClinicalTrials.gov registry record · Phase 1
Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00014755 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 35 participants.
The verdict
NCT00014755, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the toxicity of total-body irradiation, anti-thymocyte globulin, and cyclophosphamide followed by syngeneic or autologous peripheral blood stem cell (PBSC) transplantation in patients with multiple sclerosis. II. Determine the disease response of patients treated with this regimen. III. Determine the safety and efficacy of filgrastim (G-CSF) for PBSC mobilization in this patient population.
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG filgrastim
- PROCEDURE peripheral blood stem cell transplantation
- DRUG anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 1997-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014755
The ClinicalTrials.gov registry entry for NCT00014755 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00014755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014755 about?
NCT00014755 is a clinical study titled "Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis". OBJECTIVES: I. Determine the toxicity of total-body irradiation, anti-thymocyte globulin, and cyclophosphamide followed by syngeneic or autologous peripheral blood stem cell (PBSC) transplantation in patients with multiple sclerosis. II. Determine the disease response of patients treated with this ...
What is the current status of trial NCT00014755?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 1997-12.
What interventions are being tested in trial NCT00014755?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), filgrastim (DRUG), peripheral blood stem cell transplantation (PROCEDURE), anti-thymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00014755?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.